<DOC>
	<DOCNO>NCT02615002</DOCNO>
	<brief_summary>This study Phase 2 , randomize , placebo control , dose range study piromelatine ( 5 , 20 , 50 mg daily 6 month ) versus placebo determine effective dose base efficacy ( cognitive performance ) , safety tolerability patient mild dementia due AD .</brief_summary>
	<brief_title>Safety Efficacy Piromelatine Mild Alzheimer 's Disease Patients ( ReCOGNITION )</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Patient caregiver willing take part entire study Signed informed consent patient caregiver Patient clearly document history either medical record informant cognitive decline least 6 month Patient mild probable AD consistent criterion establish NIAAA CT/MRI scan finding consist probable AD obtain last 12 month Screening Patient MMSE score 2126 ( inclusive ) Screening Patient Clinical Dementia Rating Global Score ( CDRGS ) 0.51 ( mild dementia ) Screening Patients receive prescribed drug treatment AD include acetyl cholinesterase inhibitor [ eg , donepezil , galantamine , rivastigmine ] stable dose least 3 month Screening Patient negative drug screen ( benzodiazepine opiate ) Screening Female patient must last natural menstruation â‰¥ 24 month Screening , OR surgically sterile Male patient must agree use effective contraception female partner childbearing potential , OR surgically sterile Patient alternative cause dementia AD determine CT MRI scan Patient evidence clinically significant neurodegenerative disease Patient diagnose follow Axis I disorder ( DSM V criterion ) Patient history uncontrolled untreated cardiovascular , endocrine , gastrointestinal , respiratory , rheumatologic disorder within past 5 year Patient severe pain likely interfere sleep Continuous use benzodiazepine sedativehypnotics 2 week Screening Use kind melatonin/melatonin agonist 2 week Screening Patient know suspected hypersensitivity exogenous melatonin melatonin receptor agonists Patients irregular lifestyle life pattern ( eg , shift worker , patient likely jet lag ) .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Cognition</keyword>
	<keyword>mild Alzheimer 's disease</keyword>
	<keyword>Sleep</keyword>
</DOC>